Lv11
40 积分 2025-10-10 加入
Bispecific T cell engager therapy for refractory rheumatoid arthritis
1个月前
已完结
BCMA-Targeted T-Cell–Engager Therapy for Autoimmune Disease
2个月前
已完结
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
2个月前
已完结
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
2个月前
已完结
Advances in the treatment of systemic lupus erythematosus
2个月前
已完结
BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease
2个月前
已完结
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
2个月前
已完结
Bivalent BCMA Binding and Low Affinity CD3 T-Cell Engagement By Abbv-383 Drives Sustained Activation with Reduced T-Cell Exhaustion in Preclinical Models of Multiple Myeloma
2个月前
已关闭
皖公网安备34019202002308
